CHA Biotech
    The Global No.1 Biomedical Company

    what's new
    · Phase 1 trial of CBT 101-Solid Cancer is ongoing (Korea)
     : Received ODD(Orphan Drug Designation) from US FDA (US)

    · Phase 1/2a trial of CordSTEM-Disk Degeneration is ongoing (Korea)
    · Recently launched global CDMO business with Matica Biotechnology, a US Subsidiary
     located in Texas (US)
    : Seasoned CDMO industry professionals joined Matica Biotechnology in key positions
    : Matica Biotechnology initiated construction of GMP production facility for viral vector production
    · Generated 2020 3Q consolidated revenue of KRW 177 bn, its highest-ever quarterly consolidated revenue
    : Accumulated revenue grew 32.5% YoY despite the impact of the COVID-19 pandemic

    · CHA Bio Lab, a Subsidiary in Korea, obtained approval to manufacture high-tech biopharmaceuticals for the first time in Korea